- Home
- Publications
- Publication Search
- Publication Details
Title
Lemborexant: First Approval
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 4, Pages 425-432
Publisher
Springer Science and Business Media LLC
Online
2020-02-24
DOI
10.1007/s40265-020-01276-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation
- (2019) Carsten Theodor Beuckmann et al. SLEEP
- 0429 Respiratory Safety of Lemborexant in Adult and Elderly Subjects with Mild Obstructive Sleep Apnea
- (2019) Jocelyn Cheng et al. SLEEP
- 0371 Lemborexant Treatment for Insomnia in Phase 3: Impact on Disease Severity
- (2019) Tom Roth et al. SLEEP
- 0370 Patient-reported Sleep Onset and Sleep Maintenance: Pooled Analyses of Lemborexant Phase 3 Studies
- (2019) Phyllis C Zee et al. SLEEP
- 0367 Lemborexant Treatment for Insomnia: 6-month Safety
- (2019) Mikko Kärppä et al. SLEEP
- Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: 12-month results from sunrise-2
- (2019) J. Yardley et al. SLEEP MEDICINE
- Impact of lemborexant treatment on the patient global impression - insomnia scale
- (2019) C. Drake et al. SLEEP MEDICINE
- The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases
- (2018) Chunmei Wang et al. Frontiers in Molecular Neuroscience
- Insomnia in Elderly Patients: Recommendations for Pharmacological Management
- (2018) Vivien C. Abad et al. DRUGS & AGING
- On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
- (2018) Annemiek Vermeeren et al. SLEEP
- Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study
- (2017) Patricia Murphy et al. Journal of Clinical Sleep Medicine
- In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist
- (2017) Carsten Theodor Beuckmann et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant
- (2016) Patricia J. Murphy et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist
- (2015) Yu Yoshida et al. JOURNAL OF MEDICINAL CHEMISTRY
- Orexin Receptors: Pharmacology and Therapeutic Opportunities
- (2011) Thomas E. Scammell et al. Annual Review of Pharmacology and Toxicology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now